Evaluating Barriers to Stroke Screening and Prevention in Children With Sickle Cell Disease



Status:Enrolling by invitation
Conditions:Neurology, Anemia
Therapuetic Areas:Hematology, Neurology
Healthy:No
Age Range:2 - 24
Updated:3/30/2019
Start Date:February 12, 2018
End Date:June 1, 2019

Use our guide to learn which trials are right for you!

DISPLACE: Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (Part 1 and 2)

DISPLACE is a three part, multi-center U.S. based study to evaluate the barriers to stroke
screening and prevention in children with sickle cell anemia (SCA). In the United States, TCD
(Transcranial Doppler ultrasound) is a proven method of screening children with SCA for
stroke. However, many children are not getting the screening they need. This study will
examine the issues that hinder and help children get the screening at 28 different hospitals
and sickle cell centers to improve care for all children with sickle cell anemia. The
investigators will then plan a study (part 3) aimed to improve stroke screening and
prevention in sickle cell anemia.

DISPLACE (Dissemination and Implementation of Stroke Prevention: Looking At the Care
Environment) is a multi-center, national NHLBI-funded grant to evaluate the real world
implementation of the STOP protocol in which transcranial Doppler (TCD), a measure of
cerebral blood vessel velocity, is used to screen for stroke risk in children ages 2-16 with
sickle cell anemia (SCA). Based on the STOP (Stroke Prevention Trial in Sickle Cell Anemia)
protocol, children identified as high risk of stroke by TCD are initiated on chronic red cell
transfusion therapy (CRCT) for stroke prevention. Children with normal TCD are screened
annually from the age of 2 until they are 16 years of age.

This will be a THREE-part study beginning with Part 1 - a retrospective case record review
followed by Part 2 - a multi-level qualitative assessment of barriers and enablers to TCD
screening and initiation of chronic red blood cell transfusions and later adding Part 3 - a
multi-center implementation clinical trial.The investigators will compare two implementation
interventions to improve TCD screening.

There are three aims of the grant and each aim is equivalent to the respective parts of the
grant (i.e. Part 1 covers 1 aim). There are a total 28 consortium sites. The Medical
University of South Carolina is the lead institution for this study.

Inclusion Criteria:

- Age is >2 and <16 at time of review (from 2012-2016)

- have documented sickle cell anemia

- primary language is English

- patient at a DISPLACE consortium institution

Caregiver Characteristics:

Parent or guardian of patient who meets above criteria Primary language is English Has the
cognitive capacity to complete questionnaires

EXCLUSION CRITERIA:

Child Characteristics:

Experiencing current acute complications of sickle cell disease requiring hospitalization
or an acute care visit (e.g., pain crises, acute chest syndrome, acute cerebrovascular
events/stroke or active infection/fever)

Caregiver Characteristics:

Has a child experiencing current acute complication of sickle cell disease, such as pain
crisis, acute chest syndrome, stroke, or infection.
We found this trial at
1
site
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials